Changjiang Pharmaceutical Group Co., Ltd.

Equities

300391

CNE100001XN8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
3.97 CNY -4.57% Intraday chart for Changjiang Pharmaceutical Group Co., Ltd. +3.93% -48.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma MT
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps MT
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023 MT
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023 MT
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts MT
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China MT
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales MT
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug MT
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5% MT
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd completed the acquisition of 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd. CI
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone MT
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd signed Share Transfer Agreement to acquire 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd. for CNY 154.14 million. CI
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Changjiang Pharma Units Sign 359 Million Yuan Contracts MT
YiChang HEC ChangJiang Pharma to Return to Profitability MT
YiChang HEC ChangJiang Pharmaceutical Shareholders to Vote on Disposal of 10% Stake in Controlling Shareholder MT
Kangyue Technology Adopts New Name After Shifting to Pharmaceuticals MT
Kangyue Technology to Change Company Name MT
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies MT
Kangyue Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Kangyue Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Kangyue Technology Co., Ltd. Announces Board Appointments CI
Chart Changjiang Pharmaceutical Group Co., Ltd.
More charts
Changjiang Pharmaceutical Group Co Ltd, formerly Kangyue Technology Co Ltd, is a China-based company principally engaged in the research and development, production and sales of drugs. The Company is engaged in three businesses. The pharmaceutical business is engaged in traditional Chinese medicine decoction pieces business, medicinal capsule business and pharmaceutical wholesale business. The internal combustion engine parts business is engaged in the research and development, production and sales of turbocharger products. The photovoltaic equipment business is engaged in the research and development, production and sales of photovoltaic equipment such as laminator and stitch welding machine.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300391 Stock
  4. News Changjiang Pharmaceutical Group Co., Ltd.
  5. China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug